Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles

Abbott is maintained as a Buy and is described as undervalued at $109.56 despite recent execution missteps and Nutrition-segment weakness. Core Devices and Diagnostics are reporting high single-digit sales growth and double-digit EPS growth, underpinning the investment thesis, while management expects a Nutrition turnaround in H2. The potential Exact Sciences acquisition could add a new high-growth vertical, though Nutrition remains the primary downside risk.

Analysis

Winners from a Nutrition soft patch are likely to be concentrated: distributors and big-box retailers will temporarily regain pricing leverage as brands push promotions to clear inventory, pressuring upstream co-packers and commodity suppliers (whey, lactose, vegetable oils) for 2–3 quarters of margin compression. Conversely, Abbott’s high-margin consumables and capital-equipment franchises create a defensive earnings stream that can fund either buybacks or M&A even if Nutrition lags; this increases the probability that management levers capital allocation rather than structural cost cutting to hit EPS targets.

The Nutrition turnaround is a timing and sequencing problem: a genuine H2 recovery requires visible channel destocking completion, a non-promotional shelf reset, and stable household demand — expect 3–6 months to see inventory metrics normalise and 6–12 months to see meaningful revenue re-acceleration. Tail risks include renewed regulatory scrutiny or another supply-chain shock, which would push the recovery into a multi-year rehabbing exercise and force multiple compression even with continued Diagnostics growth.

The potential addition of a diagnostics/cancer-screening asset introduces both optionality and integration risk. Near-term EPS dilution and one-time costs are likely; mid-term upside comes from cross-selling into existing clinician and lab channels and accelerating recurring testing revenues. The market is likely underpricing the optionality of cross-sell revenue and overpricing near-term Nutrition cyclicality — meaning a disciplined play that monetises downside protection while keeping upside exposure to Diagnostics-led re-rating has asymmetric payoff potential.

Key Decisions for Investors

• Long ABT equity (size 3–6% NAV), horizon 12–18 months. Target ~+20% total return if Diagnostics re-rating and Nutrition stabilise; use a hard stop at -10% intraperiod or hedge with 6–9 month 5–7% OTM puts to limit drawdown to ~8–10% (expect cost ~1–2% of NAV depending on strikes).
• Options collar to express asymmetric upside: buy 12-month ABT 12-month 120/150 call spread (or nearest liquid strikes) while selling 6–9 month 5–10% OTM puts to fund premium. This preserves upside (capped) while monetising near-term volatility; suitable for 1–3% tactical allocations.
• Small stochastic M&A optionality trade on EXAS (size 0.5–1% NAV). Buy EXAS shares or long-dated calls with a 6–12 month horizon to capture upside if acquisition/partnership surfaces; cap exposure small due to execution/integration risk and potential takeover premium volatility.
• Pair trade for idiosyncratic Nutrition risk: long ABT / short a consumer nutrition peer or index (size net market exposure 1–3% NAV) over next 3–9 months to isolate Diagnostics upside from category-specific downside. Trim if channel inventory indicators (retailer sell-through, distributor inventory days) show normalisation.
• Triggers & risk management: set alerts for (1) quarterly guidance changes, (2) retailer/distributor inventory disclosures, (3) FDA or regulatory announcements, and (4) any EXAS deal terms. Reduce net exposure by 30–50% if Nutrition guidance is cut again or if regulatory enforcement actions emerge.